WO1996019997A1 - Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption - Google Patents
Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption Download PDFInfo
- Publication number
- WO1996019997A1 WO1996019997A1 PCT/EP1995/005106 EP9505106W WO9619997A1 WO 1996019997 A1 WO1996019997 A1 WO 1996019997A1 EP 9505106 W EP9505106 W EP 9505106W WO 9619997 A1 WO9619997 A1 WO 9619997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- phenyl
- estra
- dien
- llß
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of at least one compound with progesterone-antagonistic (PA) and at least one compound with anti-estrogenic (A ⁇ ) activity, in each case in non-ovulation-inhibiting dosage in a single dose unit, for the production of medicaments for female contraception.
- PA progesterone-antagonistic
- a ⁇ anti-estrogenic
- the medicaments produced according to the invention develop their contraceptive effect on the basis of the receptivity inhibition by preventing a fertilized egg from implanting in the uterine mucosa without disturbing the ovulation or the cycle.
- the contraceptive effect of a progesterone antagonist is due on the one hand to the ovulation-inhibiting effect and on the other hand to direct effects on the endometrium.
- RU 486-type progesterone antagonists are poorly dissociated compounds with a strong ovulation-inhibiting effect.
- Progesterone antagonists of the onapristone type are endometrium-specific (strongly dissociated) compounds that only inhibit ovulation at high doses. Chronic treatment with such progesterone antagonists leads to growth retardation of the endometrium, whereby the ovarian and menstrual cycle is not disturbed. In the endometrium, endometrial glands degenerate and the stroma is compressed, so that the implantation of a fertilized egg is prevented (inhibition of receptivity).
- RU 468 can be used for a therapeutically induced termination of pregnancy (the human abortive dose in combination with a Prostaglandin is 200-600 mg; EP-A 0 139 608), but on the other hand can also be used for the therapy of Cushing's syndrome due to its antagonistic effect on the glucocorticoid receptor.
- EP-A 0 219 447 describes the effects of daily administration of a progesterone antagonist during the follicular or, optionally, also the luteal phase of the female cycle in a period of up to 4 days in one dose of 10-200 mg with respect to the endometrial differentiation state.
- the resulting changes in the endometrium are used for in vitro fertilization with regard to the time of nidation.
- the hormonal control of the implantation depends on the species. In all mammals examined so far, the presence of ovarian progesterone is necessary for successful implantation. In postcoital ovariectomized rats and mice that are substituted with progesterone, there is no implantation without estrogen administration (Finn CA, Porter DG [1975] Implantation of ova [Chapter 6] and The control of implantation and the decidual reaction [Chapter 8] ; In Finn CA and Porter [eds] The Uterus, Elek Science, L.ondon, pp 57-73; 86-95). If estrogen is injected into these animal species, the blastocyst is immediately implanted (delayed implantation model).
- ovarian estrogen induces rodent implantation in the presence of progesterone. It was already known that in guinea pigs and primates, ovarian estrogens are not essential for implantation. In guinea pigs that were ovariectomized after mating, the implantation only takes place after progesterone substitution (without additional estrogen treatment) (Deansley R [1972] Retarded embryonic development and pregnancy termination in ovariectomized guinea pigs: progesterone deficiency and decidual collapse; J Reprod Fert [1972 ] 28: 241-247).
- DE-A 42 13 005 shows the use of aromatase inhibitors for contraception in female primates of reproductive age in a dosage at which the menstrual cycle of the female primate remains essentially unaffected.
- Aromatase inhibitors block the biosynthesis of estrogens from their metabolic precursors.
- the absolute amount of the daily doses required for the contraceptive effect depends entirely on the type of aromatase inhibitor used. For highly active aromatase inhibitors, the daily doses are usually between about 0.05 to about 30 mg. With less active aromatase inhibitors, the daily doses can also be higher.
- the present invention has for its object to provide a preparation for endometrial contraception (inhibition of endometrial receptivity, post-coital use, "need pill”), which does not show the undesirable side effect mentioned above and at the same time a higher contraceptive Security as the separate application of the corresponding individual components.
- a “need pill” is to be understood as an orally administered medicament which prevents a conception when it is preferably used once and precoitally as required.
- Such an agent, produced using only a competitive progesterone antagonist, is described in the unpublished German patent application P 44 38 820.9.
- At least one compound with progesterone-antagonistic (PA) and at least one compound with anti-estrogenic (A ⁇ ) activity are used together for the production of medicaments for female contraception.
- Agent containing at least one compound with antigestagenic and at least one compound with anti-estrogenic activity, in particular for induction of birth and termination of pregnancy and for the treatment of gynecological disorders, and the use of at least one compound with antigestagenic and at least one compound with anti-estrogenic activity for the production of medicaments for the indicated indications are already the subject of EP-A 0 310 541.
- compositions for post-coital fertility control which contain a competitive progesterone antagonist (antigestagen) and a progesterone and estrogen synthesis blocker, have already been described in US Pat. No. 4,670,426.
- Typical representatives of the competitive progesterone antagonist to be used are fluocrnolone acetonide, triamcinolone acetonide, steroids with a cyclic 16,17 acetal with acetone and IIß- [4- (dimethylamino) phenyl] -17ß- hydroxy-17 ⁇ - (l-propynyl) estra-4,9-dien-3-one (RU 38 486) and equivalent derivatives mentioned.
- the typical content is between 20 and 50 mg.
- Examples of the progesterone and estrogen synthesis blocker are aminoglutethimide, 4 ⁇ , 17 ⁇ -dimethyl-17ß-hydroxy-3-oxo-4 ⁇ , 5-epoxy-5 ⁇ -androstan-2-carbonitrile, 20.25-
- Diazocholesterol and compounds with equivalent activity are listed in a dose of 300 to 1000 mg.
- the composition must be used as early as possible within the first week after sexual intercourse over a period of 3 days; it is best to continue treatment for 2 to 6 days.
- the prevention of nidation and thus pregnancy is achieved by the synergistic effect when the two components of the composition are used together, with a success rate of the order of 90% or more.
- the main advantages of the present invention lie not least in the low dosage of the active ingredients, on the one hand due to the possible reduction in the effective amounts required for monotherapy due to the synergistic effect, and on the other hand through the use of lower, non-ovulation-inhibiting dosages.
- the cyclicality of the female menstrual cycle is in no way impaired (as caused by ovulation-inhibiting substances such as RU 486) and the organism is not burdened by unnecessarily high amounts of the competitive progesterone antagonist or the anti-estrogen.
- progesterone antagonist / anti-estrogen combination offers safe contraception, ie the regular use of such a medication (daily, regularly every 3 to 7 days) prevents the blastocyst from implanting without affecting the cycle. Furthermore, the contraceptive security is increased after a one-time, needs-based precoital intake regardless of the intake day in the cycle ("need pill") or after postcoital treatment.
- estrogen deprivation Due to the dose reduction of the anti-estrogen, estrogen deprivation is not to be expected. In this way, an endometrium-selective effect of the anti-estrogen can be achieved and an unfavorable effect due to estrogen deprivation on other organs, for example on the bone, can be avoided.
- the weight ratio of both components in the new drug can be varied within wide limits. Both the same amounts of PA and A ⁇ and an excess of one of the two components can be used. PA and A ⁇ are used together, separately, simultaneously in a weight ratio of essentially 50: 1 to 1:50, preferably 25: 1 to 1:25, and in particular 10: 1 to 1:10. Co-administration is preferred. PA and A ⁇ can preferably be applied in combination in one dose unit.
- the two components can be applied once a day or intermittently every 3-6 days over the entire cycle. They can also be used once precoitally (as required; "pill on demand") regardless of the time of the menstrual cycle or postcoitally. In the case of precoital use, the progesterone antagonist is dosed higher, but below the ovulation-inhibiting dose.
- progesterone receptor progestogen receptor
- progesterone antagonists All compounds which competitively block the effect of progesterone on the progestogen receptor (progesterone receptor) and which do not show their own progestogen activity are possible as competitive progesterone antagonists; the blockage can be brought about by the substance administered itself or by its metabolites.
- the competitive progesterone antagonists are preferably endometrium-specific (dissociated) compounds which at most have weak antiovulatory activity.
- Non-dissociated progesterone antagonists can also be used, in which case their Dosage is below the ovulation-inhibiting dose.
- the following steroids are possible:
- typical examples of competitive progesterone antagonists to be used according to the invention are: IIß- [4- (dimethylamino) phenyl] -17 ⁇ -hydroxy-17ß- (3-hydroxypropyl) -13 ⁇ -estra-4,9-dien-3-one (EP-A-0 129 499);
- the latter PAs are of the dissociated type, in which changes in the endometrium are observed at a certain threshold dose, while the ovulation (central effect) is not inhibited.
- the quotient of the ovulation-inhibiting and abortive dose (dissociation factor) can serve as a measure of the dissociation. Dissociated PAs are preferred in the context of the present invention.
- the competitive progesterone antagonists can, for example, be applied locally, topically, enterally, transdermally or parenterally.
- tablets, dragees, capsules, pills, suspensions or solutions are particularly suitable, which can be prepared in the usual way with the additives and carrier substances customary in galenics.
- vaginal suppositories, vaginal gels, implants, vaginal rings, intrauterine release systems (IUDs) or transdermal systems such as skin patches are suitable.
- One unit dose contains about 0.25 to 50 mg of llß- [4- (dimethylamino) phenyl] - 17 ⁇ -hydroxy-17ß- (3-hydroxypropyl) -13 ⁇ -estra-4,9-dien-3-one or a biologically equivalent Amount of another competitive progesterone antagonist. Effective amounts are determined in the niditation inhibition test on guinea pigs (treatment day 1-7 post coitum).
- the pharmaceutical agent produced according to the invention is applied by means of an implant, a vaginal ring, an IUD or a transdermal system, these application systems must be designed in such a way that the dose of the competitive progesterone antagonist released by them daily in this range of 0.25 to 50 mg lies.
- the dose of a competitive progesterone antagonist to be applied according to the invention can be in the non-ovulation-inhibiting and non-abortion-triggering dose range of the progesterone antagonist in question.
- the most suitable compounds having an anti-estrogen effect are estrogen antagonists (competitive anti-estrogens).
- Estrogen antagonists according to the present invention can either be derived from steroids or be non-steroidal compounds.
- Estrogen antagonists according to the present invention are only to be understood as those compounds which act as selectively as possible, i.e. which essentially only inhibit the effect of estrogens and / or lower their concentration. The estrogen antagonists work by displacing estrogen from the receptor.
- estrogen antagonists All common compounds with a competitive anti-estrogenic effect on the receptor can be considered as estrogen antagonists. They can be used in approximately the same amounts as the estrogen antagonists already on the market, that is to say the daily dose is about 5-100 mg for tamoxifen or the biologically equivalent amount of another estrogen antagonist.
- non-steroidal estrogen antagonists are: (Z) -N r N-dimethyl-2- [4- (1,2-diphenyl-l-butenyl) phenoxy] ethanamine (tamoxifen), l- [2- [4- (3,4-dihydro-6-methoxy-2-phenyl-l-naphthalinyl) phenoxy] ethyl] pyrrolidine hydrochloride ( ⁇ afoxidin), ⁇ .
- steroidal estrogen antagonists which may also be used are, for example: 17 ⁇ -ethynyl-11 ⁇ -methylestra-1,3,5 (10) -triene-3,17ß-diol and 16ß-ethyltra-1,3,5 (10) -triene-3, 17ß-diol,
- estrogen antagonists which act particularly strongly and as selectively as possible on the endometrium (for example tamoxifen, ifenafoxidin, 7 ⁇ - [9 - [(4, 4,5,5, 5-pentafluoropentyl) sulfinyl] nonyl] estral , 3,5 (10) -triene-3,17 ⁇ -diol).
- the threshold dose for endometrium-selective action is determined in ovariectomized, estradiol-substituted rats. Mitotic activity serves as a parameter (proliferation marker: PC ⁇ A).
- the threshold dose is the amount of the estrogen antagonist at which only an effect on the uterus, namely an inhibition of the estrogen-induced proliferation of the endometrium, is observed.
- Aromatase inhibitors in connection with progesterone antagonists can also be used as anti-estrogens according to the present invention.
- Aromatase inhibitors suppress the synthesis of estrogens from their precursors.
- the use of estrogen antagonists is preferred over that of aromatase inhibitors in any case, since the estrogen antagonists reduce the serum Do not affect estrogen concentration
- An A ⁇ dose unit contains 0.01-100 mg tamoxifen or a biologically equivalent amount of another anti-estrogenic compound.
- Progesterone antagonistic and anti-estrogenic compounds can e.g. B. locally, topically, enterally or parenterally.
- the progesterone antagonist and the anti-estrogen are preferably used in a common dosage unit.
- Tablet press is manufactured. If appropriate, the active compounds according to the invention, each with half of the additives indicated above, can also be pressed separately into a two-layer tablet.
- Tablet press is manufactured. If appropriate, the active compounds according to the invention, each with half of the additives indicated above, can also be pressed separately into a two-layer tablet.
- Tablet press is manufactured. If appropriate, the active compounds according to the invention, each with half of the additives mentioned above, can also be pressed separately into a two-layer tablet.
- Example 5 the active compounds according to the invention, each with half of the additives mentioned above, can also be pressed separately into a two-layer tablet.
- the solution is filled into an ampoule
- Tablet press is manufactured. If appropriate, the active compounds according to the invention, each with half of the additives indicated above, can also be pressed separately into a two-layer tablet.
- the experiments were carried out on intact guinea pigs with a normal cycle. Treatment started on day 1 post coitum. The animals were treated with vehicle (benzyl benzoate / castor oil) or the tamoxifen in a dose of 0.3, 1, 3 mg / day animal or the progesterone-antagonistically active compound onapristone (0.3, 1.0, 3.0 mg / Day / animal), each alone, or treated with a combination of both compounds. The substances were applied subcutaneously. The number of implantation sites on day 12 post coitum serves as a parameter.
- Tamoxifen 0.5 mg leads to a significant increase in effectiveness (synergism).
- Receptivity inhibition means a complete avoidance of
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9510550A BR9510550A (pt) | 1994-12-23 | 1995-12-23 | Compostos com ação antagonista de progesterona e antiestrogénio para utilização combinada para a contracepção feminina |
CZ19971953A CZ288062B6 (cs) | 1994-12-23 | 1995-12-23 | Přípravek pro ženskou antikoncepci |
NZ298769A NZ298769A (en) | 1994-12-23 | 1995-12-23 | use of progesterone-antagonistic and anti-estrogen compounds in a single dose for female contraception |
SI9520136A SI9520136A (en) | 1994-12-23 | 1995-12-23 | Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception |
EP95943194A EP0799042A1 (de) | 1994-12-23 | 1995-12-23 | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption |
SK789-97A SK284538B6 (sk) | 1994-12-23 | 1995-12-23 | Progesterónantagonisticky a antiestrogénne účinné zlúčeniny na spoločné použitie na výrobu ženskej antikoncepcie |
EE9700143A EE03421B1 (et) | 1994-12-23 | 1995-12-23 | Progesteroonantagonistlike ja antiöstrogeensete omadustega ühendid kombineeritud kasutamiseks naiste kontratseptsioonil |
JP8520204A JPH10511378A (ja) | 1994-12-23 | 1995-12-23 | 女性の避妊のための共通使用のためのプロゲステロン拮抗及び抗エストロゲン作用を有する化合物 |
PL95320786A PL183843B1 (pl) | 1994-12-23 | 1995-12-23 | Kompozycja farmaceutyczna do antykoncepcji żeńskiej i sposób jej wytwarzania |
AU44337/96A AU710819B2 (en) | 1994-12-23 | 1995-12-23 | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
RO97-01061A RO121086B1 (ro) | 1994-12-23 | 1995-12-23 | Utilizarea compuşilor cu proprietăţi antiestrogene, pentru controlul fertilităţii la femei |
BG101553A BG62384B1 (bg) | 1994-12-23 | 1997-06-03 | Прогестероново-антагонистични и антиестрогенови активнисъединения с общо приложение за женски контрацептиви |
FI972623A FI972623A0 (fi) | 1994-12-23 | 1997-06-18 | Progesteroniantagonisteina ja antiestrogeeneina vaikuttavia yhdisteitä käytettäväksi yhdessä naisilla raskaudenestoon |
NO19972877A NO314066B1 (no) | 1994-12-23 | 1997-06-20 | Anvendelse av en forbindelse med progesteronantagonistisk (PA) virkning ogminst ±n forbindelse med antiöstrogen (AÖ)-virkning forfremstilling av et middel beregnet for kombinert anvendelse for antikonsepsjon hos kvinner |
LVP-97-124A LV11883B (lv) | 1994-12-23 | 1997-06-20 | Savienojumi ar antiprogestīna un antiestrogēna iedarbību kopējai izmantošanai sievietes kontracepcijai |
MXPA/A/1997/004742A MXPA97004742A (es) | 1994-12-23 | 1997-06-23 | Compuestos con propiedades antagonistas de progesterona y anti-estrogeno para su uso combinado en la anticoncepcion femenina |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4447402.4 | 1994-12-23 | ||
DE4447402 | 1994-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996019997A1 true WO1996019997A1 (de) | 1996-07-04 |
Family
ID=6537602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/005106 WO1996019997A1 (de) | 1994-12-23 | 1995-12-23 | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption |
Country Status (24)
Country | Link |
---|---|
US (1) | US6362237B1 (de) |
EP (1) | EP0799042A1 (de) |
JP (1) | JPH10511378A (de) |
KR (1) | KR100385663B1 (de) |
CN (1) | CN1075375C (de) |
AU (1) | AU710819B2 (de) |
BG (1) | BG62384B1 (de) |
BR (1) | BR9510550A (de) |
CA (1) | CA2208321A1 (de) |
CZ (1) | CZ288062B6 (de) |
EE (1) | EE03421B1 (de) |
FI (1) | FI972623A0 (de) |
HU (1) | HUT77519A (de) |
IL (1) | IL116505A0 (de) |
LT (1) | LT4291B (de) |
LV (1) | LV11883B (de) |
NO (1) | NO314066B1 (de) |
NZ (1) | NZ298769A (de) |
PL (1) | PL183843B1 (de) |
RO (1) | RO121086B1 (de) |
SI (1) | SI9520136A (de) |
SK (1) | SK284538B6 (de) |
WO (1) | WO1996019997A1 (de) |
ZA (1) | ZA9510926B (de) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024803A1 (de) * | 1996-12-06 | 1998-06-11 | Schering Aktiengesellschaft | Steroidester, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
EP0909764A1 (de) * | 1997-10-11 | 1999-04-21 | JENAPHARM GmbH | 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
WO1999024027A2 (en) * | 1997-11-06 | 1999-05-20 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
WO1999045023A1 (de) * | 1998-03-03 | 1999-09-10 | Jenapharm Gmbh & Co. Kg | S-SUBSTITUIERTE 11β-BENZALDOXIM-ESTRA-4,9-DIEN-KOHLENSÄURETHIOLESTER, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENE PHARMAZEUTISCHE ZUBEREITUNGEN |
WO2000066574A1 (en) * | 1999-05-04 | 2000-11-09 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
FR2803516A1 (fr) * | 2000-01-10 | 2001-07-13 | Astrazeneca Ab | Formulation injectable de fulvestrant |
US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6399593B1 (en) | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
US6436929B1 (en) | 1999-05-04 | 2002-08-20 | Wyeth | Cyclothiocarbamate derivatives as progesterone receptor modulators |
US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
JP4382735B2 (ja) | 2005-10-06 | 2009-12-16 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
US20090170823A1 (en) * | 2007-12-20 | 2009-07-02 | Duramed Pharmaceuticals, Inc. | Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0310541A1 (de) * | 1987-10-01 | 1989-04-05 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Geburtseinleitung und zum Schwangerschaftsabbruch sowie zur Behandlung gynäkologischer Störungen |
EP0310542A1 (de) * | 1987-10-01 | 1989-04-05 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2824733C2 (de) | 1978-06-06 | 1984-03-15 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Umführtrommel für Schön- und Widerdruckmaschinen |
ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
IL68222A (en) * | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
ES8502612A1 (es) | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
DE3322285A1 (de) | 1983-06-18 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3337450A1 (de) | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandine und antigestagene fuer den schwangerschaftsabbruch |
AU580843B2 (en) | 1985-02-07 | 1989-02-02 | Schering Aktiengesellschaft | 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them |
DE3533175A1 (de) | 1985-09-13 | 1987-03-19 | Schering Ag | Antigestagene zur verschiebung der endometrialen reifung |
IE60780B1 (en) | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
ES2045082T3 (es) | 1987-04-24 | 1994-01-16 | Akzo Nv | Un metodo para la preparacion de nuevos derivados 11-arilestrano y 11-arilpregnano. |
ES2053714T3 (es) | 1987-12-12 | 1994-08-01 | Akzo Nv | Proceso para la preparacion de 11-arilesteroides. |
GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
DE3921059A1 (de) * | 1989-06-23 | 1991-01-10 | Schering Ag | 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
DE3926365A1 (de) | 1989-08-04 | 1991-02-07 | Schering Ag | Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln |
CH683151A5 (de) | 1991-04-24 | 1994-01-31 | Ciba Geigy Ag | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. |
EP0637296A4 (de) | 1992-04-21 | 1996-02-07 | Ligand Pharm Inc | Nicht-steroide verbindungen mit agonistischer und antagonistischer aktivität am progesteronrezeptor und verfahren zu ihrer verwendung. |
US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
-
1995
- 1995-12-21 ZA ZA9510926A patent/ZA9510926B/xx unknown
- 1995-12-22 IL IL11650595A patent/IL116505A0/xx not_active IP Right Cessation
- 1995-12-23 NZ NZ298769A patent/NZ298769A/xx unknown
- 1995-12-23 SK SK789-97A patent/SK284538B6/sk unknown
- 1995-12-23 EE EE9700143A patent/EE03421B1/xx not_active IP Right Cessation
- 1995-12-23 KR KR1019970704319A patent/KR100385663B1/ko not_active IP Right Cessation
- 1995-12-23 RO RO97-01061A patent/RO121086B1/ro unknown
- 1995-12-23 BR BR9510550A patent/BR9510550A/pt not_active IP Right Cessation
- 1995-12-23 JP JP8520204A patent/JPH10511378A/ja not_active Ceased
- 1995-12-23 CA CA002208321A patent/CA2208321A1/en not_active Abandoned
- 1995-12-23 SI SI9520136A patent/SI9520136A/sl not_active IP Right Cessation
- 1995-12-23 WO PCT/EP1995/005106 patent/WO1996019997A1/de active IP Right Grant
- 1995-12-23 CZ CZ19971953A patent/CZ288062B6/cs not_active IP Right Cessation
- 1995-12-23 CN CN95197051A patent/CN1075375C/zh not_active Expired - Fee Related
- 1995-12-23 AU AU44337/96A patent/AU710819B2/en not_active Ceased
- 1995-12-23 HU HU9702074A patent/HUT77519A/hu unknown
- 1995-12-23 PL PL95320786A patent/PL183843B1/pl not_active IP Right Cessation
- 1995-12-23 EP EP95943194A patent/EP0799042A1/de not_active Withdrawn
- 1995-12-26 US US08/578,222 patent/US6362237B1/en not_active Expired - Fee Related
-
1997
- 1997-06-03 BG BG101553A patent/BG62384B1/bg unknown
- 1997-06-18 FI FI972623A patent/FI972623A0/fi unknown
- 1997-06-20 LV LVP-97-124A patent/LV11883B/xx unknown
- 1997-06-20 NO NO19972877A patent/NO314066B1/no unknown
- 1997-06-20 LT LT97-107A patent/LT4291B/lt not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0310541A1 (de) * | 1987-10-01 | 1989-04-05 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Geburtseinleitung und zum Schwangerschaftsabbruch sowie zur Behandlung gynäkologischer Störungen |
EP0310542A1 (de) * | 1987-10-01 | 1989-04-05 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096732A (en) * | 1996-12-06 | 2000-08-01 | Schering Ag | Steroid esters, process for their production and their pharmaceutical use |
WO1998024803A1 (de) * | 1996-12-06 | 1998-06-11 | Schering Aktiengesellschaft | Steroidester, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
EP0909764A1 (de) * | 1997-10-11 | 1999-04-21 | JENAPHARM GmbH | 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
WO1999024027A2 (en) * | 1997-11-06 | 1999-05-20 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
WO1999024027A3 (en) * | 1997-11-06 | 1999-07-15 | American Home Prod | Anti-estrogen plus progestin containing oral contraceptives |
US6365582B1 (en) | 1998-03-03 | 2002-04-02 | Jenapharm Gmbh & Co. Kg | S-substitute 11β-benzaldoxime-estra-4, 9-diene-carbonic acid thiolesters, method for the production thereof and pharmaceutical preparations containing these compounds |
WO1999045023A1 (de) * | 1998-03-03 | 1999-09-10 | Jenapharm Gmbh & Co. Kg | S-SUBSTITUIERTE 11β-BENZALDOXIM-ESTRA-4,9-DIEN-KOHLENSÄURETHIOLESTER, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENE PHARMAZEUTISCHE ZUBEREITUNGEN |
US6441019B2 (en) | 1999-05-04 | 2002-08-27 | Wyeth | Cyclocarbamate and cyclic amide derivatives |
US6503939B2 (en) | 1999-05-04 | 2003-01-07 | Wyeth | Combination regimens using 3,3-substituted indoline derivatives |
US7081457B2 (en) | 1999-05-04 | 2006-07-25 | Wyeth | Cyclothiocarbamate derivatives as progesterone receptor modulators |
US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6982261B2 (en) | 1999-05-04 | 2006-01-03 | Wyeth | Cyanopyrroles |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6946454B2 (en) | 1999-05-04 | 2005-09-20 | Wyeth | Thio-oxindole derivatives |
US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6399593B1 (en) | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
US6436929B1 (en) | 1999-05-04 | 2002-08-20 | Wyeth | Cyclothiocarbamate derivatives as progesterone receptor modulators |
WO2000066574A1 (en) * | 1999-05-04 | 2000-11-09 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6835744B2 (en) | 1999-05-04 | 2004-12-28 | Wyeth | 3,3-substituted indoline derivatives |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6521657B2 (en) | 1999-05-04 | 2003-02-18 | Wyeth | Thio-oxindole derivatives |
US6544970B2 (en) | 1999-05-04 | 2003-04-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6562857B2 (en) | 1999-05-04 | 2003-05-13 | Wyeth | Cyanopyrroles |
US6566358B2 (en) | 1999-05-04 | 2003-05-20 | Wyeth | Cyclocarbamate derivatives as progesterone receptor modulators |
US6583145B1 (en) | 1999-05-04 | 2003-06-24 | Wyeth | Thio-oxindole derivatives |
US6608068B2 (en) | 1999-05-04 | 2003-08-19 | Wyeth | Indoline derivatives |
US6693103B2 (en) | 1999-05-04 | 2004-02-17 | Wyeth | 1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators |
US6713478B2 (en) | 1999-05-04 | 2004-03-30 | Wyeth | Cyclocarbamate derivatives as progesterone receptor modulators |
US6759408B2 (en) | 1999-05-04 | 2004-07-06 | Wyeth | Combination regimens using progesterone receptor modulators |
US6794373B2 (en) | 1999-05-04 | 2004-09-21 | Wyeth | Contraceptive methods using benzimidazolones |
KR100802366B1 (ko) * | 2000-01-10 | 2008-02-13 | 아스트라제네카 아베 | 풀베스트란트 제제 |
US7456160B2 (en) | 2000-01-10 | 2008-11-25 | Astrazeneca Ab | Formulation |
FR2803516A1 (fr) * | 2000-01-10 | 2001-07-13 | Astrazeneca Ab | Formulation injectable de fulvestrant |
BE1013477A3 (fr) * | 2000-01-10 | 2002-02-05 | Astrazeneca Ab | Formulation. |
EP1669073A2 (de) * | 2000-01-10 | 2006-06-14 | AstraZeneca AB | Fulvestrant Formulierung |
NL1017075C2 (nl) * | 2000-01-10 | 2001-09-25 | Astrazeneca Ab | Preparaat. |
WO2001051056A1 (en) * | 2000-01-10 | 2001-07-19 | Astrazeneca Ab | Fulvestrant formulation |
EP1669073A3 (de) * | 2000-01-10 | 2008-03-19 | AstraZeneca AB | Fulvestrant Formulierung |
US6774122B2 (en) | 2000-01-10 | 2004-08-10 | Astrazeneca Ab | Formulation |
EP2266573A1 (de) * | 2000-01-10 | 2010-12-29 | AstraZeneca AB | Fulvestrant Formulierung |
EP2286818A1 (de) * | 2000-01-10 | 2011-02-23 | AstraZeneca AB | Fulvestrant Formulierung |
US8329680B2 (en) | 2000-01-10 | 2012-12-11 | Astrazeneca Ab | Formulation |
US8466139B2 (en) | 2000-01-10 | 2013-06-18 | Astrazeneca Ab | Formulation |
CZ304689B6 (cs) * | 2000-01-10 | 2014-09-03 | Astrazeneca Ab | Farmaceutický přípravek obsahující fulvestrant a jeho použití pro výrobu léčiva |
RU2263507C9 (ru) * | 2000-01-10 | 2020-03-18 | Астразенека Аб | Композиция фульвестранта |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996019997A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption | |
EP0723439B1 (de) | Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen | |
EP0310541B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Geburtseinleitung und zum Schwangerschaftsabbruch sowie zur Behandlung gynäkologischer Störungen | |
DE69532894T2 (de) | Verfahren zur empfängnisverhütung | |
DE60216630T2 (de) | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie | |
EP0772441B1 (de) | Progesteronantagonist und gestagen zur behandlung der endometriose und leiomyomata uteri | |
DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
DE4344463A1 (de) | Kombinationsprodukt zur Kontrazeption | |
EP0787002B1 (de) | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle | |
DE602004009288T2 (de) | Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose | |
DE60036723T2 (de) | Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen | |
DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
DE4329344A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri | |
EP0889727B1 (de) | Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie | |
DE4216004B4 (de) | Verwendung kompetitiver Progesteronantagonisten | |
EP0814803B1 (de) | Verwendung von steroidalen Estrogenrezeptorantagonisten zur männlichen Fertilitätskontrolle | |
MXPA97004742A (es) | Compuestos con propiedades antagonistas de progesterona y anti-estrogeno para su uso combinado en la anticoncepcion femenina | |
WO1996029078A1 (de) | OVULATIONSHEMMENDES MITTEL ZUR HORMONALEN KONTRAZEPTION DAS 50-70 νg LEVONORGESTREL UND MEHR ALS 30-40 νg ETHINYLESTRADIOL ENTHÄLT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197051.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ EE FI HU JP KR LT LV MX NO NZ PL RO RU SG SI SK UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 97-01061 Country of ref document: RO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 972623 Country of ref document: FI |
|
ENP | Entry into the national phase |
Ref document number: 2208321 Country of ref document: CA Ref document number: 2208321 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 78997 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 97-107 Country of ref document: LT Ref document number: 298769 Country of ref document: NZ Ref document number: PV1997-1953 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970704319 Country of ref document: KR Ref document number: PA/a/1997/004742 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995943194 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995943194 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 97-107 Country of ref document: LT |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-1953 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 97-107 Country of ref document: LT |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970704319 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-1953 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970704319 Country of ref document: KR |